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Abstract
Antimicrobial resistance (AMR) poses a threat to public health. Clinical microbiology laboratories typically rely on culturing 
bacteria for antimicrobial- susceptibility testing (AST). As the implementation costs and technical barriers fall, whole- genome 
sequencing (WGS) has emerged as a ‘one- stop’ test for epidemiological and predictive AST results. Few published compari-
sons exist for the myriad analytical pipelines used for predicting AMR. To address this, we performed an inter- laboratory study 
providing sets of participating researchers with identical short- read WGS data from clinical isolates, allowing us to assess the 
reproducibility of the bioinformatic prediction of AMR between participants, and identify problem cases and factors that lead to 
discordant results. We produced ten WGS datasets of varying quality from cultured carbapenem- resistant organisms obtained 
from clinical samples sequenced on either an Illumina NextSeq or HiSeq instrument. Nine participating teams (‘participants’) 
were provided these sequence data without any other contextual information. Each participant used their choice of pipeline 
to determine the species, the presence of resistance- associated genes, and to predict susceptibility or resistance to amikacin, 
gentamicin, ciprofloxacin and cefotaxime. We found participants predicted different numbers of AMR- associated genes and 
different gene variants from the same clinical samples. The quality of the sequence data, choice of bioinformatic pipeline and 
interpretation of the results all contributed to discordance between participants. Although much of the inaccurate gene variant 
annotation did not affect genotypic resistance predictions, we observed low specificity when compared to phenotypic AST 
results, but this improved in samples with higher read depths. Had the results been used to predict AST and guide treatment, 
a different antibiotic would have been recommended for each isolate by at least one participant. These challenges, at the final 
analytical stage of using WGS to predict AMR, suggest the need for refinements when using this technology in clinical settings. 
Comprehensive public resistance sequence databases, full recommendations on sequence data quality and standardization in 
the comparisons between genotype and resistance phenotypes will all play a fundamental role in the successful implementa-
tion of AST prediction using WGS in clinical microbiology laboratories.
DATA SummARy
Sequence read files for all samples used in this study have 
been deposited in the European Nucleotide Archive under 
the project accession number PRJEB34513 and the following 
sample accession numbers: SAMEA5789893 (sample A-1), 
SAMEA5789894 (sample A-2), SAMEA5789895 (sample 
B-1), SAMEA5789896 (sample B-2), SAMEA5789897 (sample 
C-1), SAMEA5789898 (sample C-2), SAMEA5789899 
(sample D), SAMEA5789900 (sample E), SAMEA5789901 
(sample F), SAMEA5789902 (sample G).
InTRoDuCTIon
Antimicrobial resistance (AMR) is a major, global, public- 
health threat, with projections of up to 10 million deaths 
per annum by 2050 [1]. The World Health Organization’s 
2015 Global Action Plan on AMR identified diagnostics 
as a priority area for combating resistance [2]. Currently, 
most diagnostic AMR testing is phenotypic antimicrobial- 
susceptibility testing (AST) and is based on principles dating 
back to the early 20th century [3]. Molecular testing has 
facilitated the implementation of PCR assays that target key 
AMR mutations and genes [4, 5]. However, there remains an 
unmet need for truly rapid point- of- care AST [6, 7].
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Whole- genome sequencing (WGS) is emerging as a routine 
clinical test that could be used to determine the bacterial 
species, undertake transmission tracking and identify multiple 
AMR- associated mutations and genes in a single assay [8–13]. 
Whilst the initial clinical roll- out of WGS has used cultured 
bacterial isolates, metagenomics and sequencing direct from 
clinical samples are future possibilities [14–16]. Resolving the 
challenges of AMR prediction using WGS for bacteria will 
provide key advances for the application of metagenomics 
as a clinical test.
There are currently a wide array of bioinformatics tools and 
pipelines to predict AMR from WGS data [17]. These have 
generally been developed by individual researchers and 
research groups, many with no clinical expertise, and mostly 
with the same basic principle of matching the input DNA 
sequence to entries in a reference database of known AMR- 
associated gene sequences. The testing of pipelines for AMR 
prediction is typically either performed in- house [18–20] or 
done ad hoc for specific research [21–24]. Often, these tools 
are not developed with clinical application or portability in 
mind. Currently, there are no higher- order reference mate-
rials (synthetic references that contain exact components 
of interest) that are available to validate these tools. Studies 
have reported good concordance between genotype and 
phenotype on datasets they have been applied to [9, 22, 25], 
but rarely address the factors underlying situations where 
different methods may produce discordant results and how 
this discordance should be resolved.
Gaining laboratory accreditation is an important, often essen-
tial, step for tests in clinical microbiology, but is less advanced 
for clinical bioinformatics due to its comparatively recent 
development. Bioinformatic reproducibility studies have been 
performed for clinically relevant bacterial sequence typing 
methods [26, 27]. However, while there have been intra- 
laboratory studies comparing methods of AMR prediction, 
there have been no comparisons of multiple methods at the 
inter- laboratory scale. As there is limited evidence of robust, 
reproducible analyses in bioinformatic prediction of AMR 
from clinical WGS data, adoption of these methods may be 
hampered in meeting the necessary accreditation.
This multi- centre study used genomic DNA sequences from 
clinical carbapenem- resistant organisms, specifically chosen 
to be of varying quality and complexity, to identify the 
Impact Statement
Antimicrobial resistance (AMR) is now recognized as a 
worldwide public- health issue, and identifying those 
infections that are resistant to common antibiotics 
quickly and accurately is a leading priority. The improve-
ment of molecular methods of analysing bacterial DNA, 
especially whole- genome sequencing (WGS), has raised 
the possibility of using it as a single assay that can 
identify the pathogen, antibiotic susceptibility and track 
transmission. In this study, we compared methods for 
predicting AMR from bacterial DNA sequences through 
an inter- laboratory study. This is, to the best of our knowl-
edge, the first study of its kind to blind sets of partici-
pants to any contextual information on the samples 
they were analysing and they were free to choose 
any analytical pipeline they wanted. This led to varia-
tion among the methods used, but also variation in the 
results reported. Inter- laboratory studies such as these 
are useful as a precursor to the formal external quality- 
assurance schemes that come later when assays have 
been embedded into clinical service. We have shown 
that although there were discrepancies between results 
reported, these discrepancies could be traced back to 
problems such as sequence quality, database choice and 
user error, all of which can be addressed for WGS to fulfil 
its potential in clinical settings.
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Table 1. Inter- laboratory study sample characteristics
Study 
ID
Isolate species Sequencing method Carbapenemase gene Median depth of 
coverage
Comment
A-1 Klebsiella 
pneumoniae
NEBNext Ultra II+NextSeq 150 bp PE OXA-48- like 190.2× Exact duplicate of A-2
A-2 Klebsiella 
pneumoniae
NEBNext Ultra II+NextSeq 150 bp PE OXA-48- like 190.2× Exact duplicate of A-1
B-1 Enterobacter cloacae 
complex
NEBNext Ultra II+NextSeq 150 bp PE OXA-48- like 1.4× Very low coverage duplicate 
of B-2
B-2 Enterobacter cloacae 
complex
NEBNext Ultra II+NextSeq 150 bp PE OXA-48- like 142.9× High coverage duplicate of B-1
C-1 Klebsiella oxytoca Nextera DNA +HiSeq 100 bp PE OXA-48- like 37.4× Same original isolate as C-2
C-2 Klebsiella oxytoca NEBNext Ultra II+NextSeq 150 bp PE OXA-48- like 156.4× Same original isolate as C-1
D Klebsiella 
pneumoniae
NEBNext Ultra II+NextSeq 150 bp PE NDM 83.5×
E Escherichia coli Nextera DNA +HiSeq 100 bp PE IMP 20.6×
F Citrobacter freundii NEBNext Ultra II+NextSeq 150 bp PE VIM 32.5×
G Acinetobacter 
baumannii
NEBNext Ultra II+NextSeq 150 bp PE OXA-23- like and 
OXA-51- like
22.2×
PE, Paired end.
range of methods used and contributors to discordant AMR 
predictions. Participants included a mixture of independent 
individuals and teams using non- commercial AMR predic-
tion pipelines from research groups, hospital laboratories, 
public- health laboratories and clinical diagnostic companies. 
The observations made underpin our recommendations for 
future method developments.
mETHoDS
Sample collection and WGS
For the purposes of this study, a panel of ten samples (A-1, 
A-2, B-1, B-2, C-1, C-2, D, E, F and G) were generated from 
seven clinical isolates (A, B, C, D, E, F and G). The bacteria 
were isolated between 2014 and 2017 from stool specimens 
from patients attending Great Ormond Street Hospital 
(GOSH), UK, or University Hospital Galway (UHG), Ireland. 
They represented six clinically relevant bacterial pathogens, 
including diverse Enterobacterales and also Acinetobacter 
baumannii, and contained six distinct families of carbapen-
emase genes (Table 1).
Phenotypic AST was performed at UHG and GOSH using 
the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) disc diffusion method (http://www. eucast. 
org) and meropenem, ertapenem, cefotaxime, amikacin, 
gentamicin and ciprofloxacin. The isolates were confirmed 
as carbapenemase producers by PCR at a reference laboratory 
(Public Health England).
Total genomic DNA was extracted from isolate sweeps on an 
EZ1 Advanced XL instrument (Qiagen) using DNA Blood 
350 µl kits with an additional bead beating step. For eight 
samples, the NEBNext Ultra II DNA library prep kit (New 
England Biolabs) and NextSeq (Illumina) 150 bp paired- end 
sequencing was used. For two samples, the Nextera DNA 
library prep kit (Illumina) and HiSeq 100 bp paired- end 
sequencing was used (Table 1). The fastq files were depos-
ited in the European Nucleotide Archive (accession no. 
PRJEB34513).
Inter-laboratory study plan
Potential inter- laboratory participants were invited in an indi-
vidual capacity, both in person and by email, at the meeting 
‘Challenges and New Concepts in Antibiotics Research’, 
March 2018, at Institut Pasteur, France. Fifteen individuals 
were also emailed directly to participate in the study. From 
those invited, nine sets of participants agreed to take part 
in the study. We will refer to these sets as ‘participants’ 
throughout. These participants were labelled Lab_1 to Lab_9; 
‘Lab’ is used as a catch- all term for an individual or team of 
participants, who came from a mixture of research groups, 
hospital laboratories, public- health laboratories and clinical 
diagnostic companies. All participants agreed to take part in 
a personal capacity using non- commercial pipelines under 
the condition of anonymity of the results. Each participant 
was not made aware who the other invited participants were 
at that stage.
Participants were sent ten paired fastq files (labelled 
AMRIL_1 to AMRIL_10) and were blinded to their contents. 
The samples included two exact duplicates A-1 and A-2 
(renamed copies of the same fastq files). Two duplicates with 
4Doyle et al., Microbial Genomics 2020;6
different depths of coverage, B-1 and B-2 (sequenced from 
the same isolate, but with median read depths of 1.4× and 
142.9×, respectively). Two samples sequenced from the same 
isolate, C-1 and C-2 (sequenced in two different laboratories 
using HiSeq and NextSeq, respectively). The remaining four 
samples, D, E, F and G, represented diverse bacterial species 
and carbapenemases.
Participants were asked to report a species identification for 
each pair of fastq files provided, as well as the presence of 
all AMR- associated genes present in that sample. They were 
asked, using the above data, to make a categorical prediction 
on whether that sample would be resistant to ciprofloxacin, 
gentamicin, amikacin and cefotaxime. Lastly, participants 
were asked to provide a description of the analysis pipeline 
they used.
Participant analyses
Participants returned results via an Excel spreadsheet (Tables 
S1–S10, available with the online version of this article). 
Results were collated for all species identifications and 
resistant or susceptible predictions from each participant. 
Collated AMR- associated genes had each name manually 
checked between each participant to identify minor differ-
ences in nomenclature used.
Individual methods are summarized in Table 2. Briefly, all 
participants used a unique combination of a number of tools 
to analyse the samples provided and report back results. For 
species identification, seven participants used a combination 
of command line tools Kraken [28], Kraken- HLL [29], mash 
[30], Centrifuge [31] and Kmerid (https:// github. com/ phe- 
bioinformatics/ kmerid). Four participants also used the web- 
based tools wgsa (https:// pathogen. watch/), blast (https:// 
blast. ncbi. nlm. nih. gov/ Blast. cgi) and KmerFinder (https:// 
cge. cbs. dtu. dk/ services/ KmerFinder/). All participants iden-
tified species from raw reads, apart from three participants 
that used assembled reads (Lab_2, Lab_5 and Lab_8). Lab_3 
used both raw reads and assemblies to assign species ID using 
mash and wgsa, respectively. Six of the nine participating 
laboratories assembled the raw reads into a draft assembly 
before identifying AMR- associated genes. Only Lab_4, Lab_7 
and Lab_9 used methods that required no assembly of the 
reads. Of those participants assembling their reads, SPAdes 
[32] was the most common assembler used, with five partici-
pants either using it directly or using one of two wrapper 
tools that contains it, Unicycler [33] or Shovill (https:// github. 
com/ tseemann/ shovill). Lab_5 was the only participant to use 
the assembler A5- MiSeq [34]. Lab_6 was also unique as the 
only participant to use a commercial bioinformatics platform, 
Bionumerics (Applied Maths), to perform their analysis. 
For the identification of AMR- associated genes, ABRicate 
(https:// github. com/ tseemann/ abricate) and rgi [35] were 
the most popular tools used, and both take assembled reads 
as input. The other assembly- based AMR gene identifiers 
used were c- SSTAR [36] and Resfinder (https:// cge. cbs. dtu. 
dk/ services/ ResFinder/). Three tools were also used that took 
raw short reads as input and these were ariba [20], srst2 
[37] and Genefinder (https:// github. com/ phe- bioinformatics/ 
gene_ finder). All participants used one or a combination of 
three AMR databases in their analysis, and these were card 
[35], Resfinder [18] and arg- annot [38]. The full methods, 
including command line parameters and software versions, 
can be found in Supplementary methods.
RESuLTS
Bacterial species identification
Four of the nine participants identified all species correctly 
from WGS data (Table 3). This included the low depth of 
coverage (1.4×) sample B-1, where we did not expect enough 
information for a correct call. Species misidentifications of 
D and B-2 at the genus level by Lab_5 is likely to be a human 
reporting error, as they correctly identified species in B-1 from 
a very low read depth. Lab_6 used the same web- based tool 
for species identification as Lab_5 (Kmerfinder; Center for 
Genomic Epidemiology), but one error was noted where raw 
sequence reads were input instead of assembled contiguous 
sequences (Table 3).
AmR gene identification
We compared the number of AMR- associated genes reported 
by each participant in each sample and found disparities in 
the total reported (Fig. 1). Lab_1 used two different meth-
odologies for identifying AMR- associated genes; the results 
are referred to as Lab_1a and Lab_1b. The number of AMR- 
associated genes reported by each participant was affected 
by the choice of database used. Lab_1a, Lab_2, Lab_3 and 
Lab_5 all repeatedly reported the highest number of genes 
in each sample and all used the Comprehensive Antibiotic 
Resistance Database (card) as their reference database. This 
is due to card including many sequences from loosely AMR- 
associated efflux pump genes that are not found in the other 
databases. Lab_4 and Lab_9 also used card, but in combina-
tion with other databases and selectively reported genes. The 
number of AMR- associated genes reported by each partici-
pant was also found to be associated with sequence identity 
and breadth of coverage thresholds used to infer a ‘hit’. Both 
Lab_2 and Lab_8 used the lowest identity and breadth of 
coverage thresholds (75 % sequence identity and no breadth 
of coverage threshold), and Lab_2 consistently reported the 
highest number of AMR genes in each sample. While Lab_8 
reported fewer AMR- associated genes than Lab_2, it did use 
ResFinder as its reference database rather than card, and 
reported the highest number of genes compared with other 
participants using the same database.
All isolates included in this study were carbapenem resistant. 
The reporting of carbapenemase genes from WGS from all 
participants matched the reference PCR result in 91 % of 
cases (91/100) (Table 4). Eight of the ten misidentifications 
occurred in the very low depth of coverage sample B-1, as 
would be expected. Differences between reported gene 
variants of blaIMP were seen in sample E. Five participants 
reported blaIMP-1, whereas the other five reported blaIMP-34. 
This discrepancy exactly matched the reference database 
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Table 3. Species identification for each sample by each participant
Participant A-1 A-2 B-1 B-2 C-1 C-2 D E F G
Reference KP KP ECl ECl KO KO KP EC CF AB
Lab_1 KP KP ECl ECl KO KO KP EC CF AB
Lab_2 KP KP – ECl KO KO KP EC CF AB
Lab_3 KP KP Shigella phage SflV ECl KO KO KP EC Citrobacter sp. AB
Lab_4 KP KP ECl ECl KO KO KP EC Citrobacter sp. AB
Lab_5 KP KP ECl KP KO KO EC EC CF AB
Lab_6 KP KP ECl ECl – KO Klebsiella sp. EC CF AB
Lab_7 KP KP ECl ECl KO KO KP EC CF AB
Lab_8 KP KP ECl ECl KO KO KP EC CF AB
Lab_9 KP KP ECl ECl KO KO KP EC CF AB
Missing data represent no results reported. Results highlighted in bold represent discrepancies.
AB, Acinetobacter baumannii; CF, Citrobacter freundii; EC, Escherichia coli; ECl, Enterobacter cloacae; KO, Klebsiella oxytoca; KP, Klebsiella 
pneumoniae.
Fig. 1. Number of AMR- associated genes identified in each sample by each team of participants.
used with those who reported blaIMP-1 having used card and 
those who reported blaIMP-34 having used either ResFinder or 
arg- annot. While the sequences for blaIMP-34 included in each 
database are identical, the choice of blaIMP-1 reference sequence 
included in both databases only share 85 % sequence identity. 
This is due to card’s blaIMP-1 reference sequence being isolated 
from a Pseudomonas aeruginosa integron [National Center for 
Biotechnology Information (NCBI) accession no.: AJ223604] 
and arg- annot’s reference sequence from an A. baumannii 
integron (NCBI accession no.: HM036079). While there is 
variation at the nucleotide level, both encode the same IMP-1 
enzyme.
We compared all AMR- associated genes identified by each 
participant in each sample. As previously noted, the largest 
discrepancies were the 55 efflux pump gene sequences that 
were present only in card (Fig. S1). To understand the 
other factors influencing discordant reporting, we removed 
these genes that were only present in one database from our 
comparisons (Fig.  2). A pairwise comparison between all 
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Table 4. Carbapenemase genes identified for each sample by each participant and the reference laboratory PCR (Ref PCR)
Participant A-1 A-2 B-1* B-2 C-1 C-2 D E F G
Ref PCR† OXA-48- 
like
OXA-48- like OXA-48- like OXA-48- like OXA-48- like OXA-48- like NDM IMP VIM OXA-23- like+OXA-
51- like
Lab_1a‡ OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23+OXA-66
Lab_1b‡ OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23+OXA-66
Lab_2 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23+OXA-66
Lab_3 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23+OXA-66
Lab_4 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-34+IMP-9 VIM-4 OXA-23+OXA-66
Lab_5 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23
Lab_6 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23+OXA-66
Lab_7 OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23+OXA-66
Lab_8 OXA-48 OXA-48 – OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23+OXA-66
Lab_9 OXA-48 OXA-48 OXA-405 OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23+OXA-66
*Missing data represent no results reported. Results highlighted in bold represent discrepancies.
†Specific carbapenemase PCR results for each sample.
‡Lab_1 provided different results using two separate methods; these are referred to as Lab_1a and Lab_1b.
participants found that two sets of participants only reported 
the exact same genes within a sample in 2 % (18/900) of cases. 
Fourteen of these cases occurred when analysing the two iden-
tical samples (A-1 and A-2; Fig. 2). Although there was little 
agreement between participants for genes identified in A-1 
and A-2, there was complete within- participant concordance 
across both samples, exhibiting reproducibility within each 
analysis pipeline. No two participants reported the exact same 
combination of gene variants in samples B-2, C-1, D, F and G. 
There were many clear examples where participants assigned 
different gene variants to the same sequence data where the 
reference sequences only differed by a few single nucleotides. 
This can be seen in Fig. 2 amongst samples that contained 
tetracycline- resistance genes [tet(A), tet(B) and tet(C)], some 
aminoglycoside modifying enzyme gene variants [aac(3)- IIa 
and aac(3)- IIc] and β- lactamases (blaACT-14 and blaACT-18). We 
also observed differences between the same participants 
analysing samples from the same original isolate. Due to 
the very low read depth, the genes reported in B-1 bore little 
resemblance to B-2 across all participant results. However, 
even in the samples from the same isolates with sufficient 
sequencing depth (C-1 and C-2), we observed differences 
in the genes identified in four out of nine participants. This 
suggests that resequencing, and even small increases in read 
length and quality, can produce variation in results. It is worth 
noting that all but one of these differences were additional 
genes identified in C-2, which had a higher read depth than 
B-2 (156 vs 37× median read depth). The additional genes in 
C-2 included ant(3′′)−Ia (Lab_2 and Lab_8), fosA7 (Lab_2 
and Lab_8) and tet(C) (Lab_3), but the reported reference 
breadth of coverage of ant(3′′)−Ia and fosA7 was low (17 and 
75 %, respectively) and the sequence similarity between the 
purported tet(C) sequence and the reference was also low 
(75%). We also found no systematic differences in genes 
present or absent between those participants that used tools 
that required assembly of short reads first and those that took 
unassembled short reads as input (Lab_4, Lab_7 and Lab_9, 
ariba, srst2 and Genefinder, respectively).
Phenotypic and genotypic resistance concordance
Given the differences in the AMR- associated genes identi-
fied in the samples by each participant, we also compared 
predictions of antibiotic resistance to phenotypic AST results 
and each other. Two participants (Lab_2 and Lab_4) did not 
submit any results for phenotypic resistance prediction, so 
were not included in the subsequent analysis. A pairwise 
comparison between genotypic prediction results reported 
by all participants, on all antibiotics and samples, showed 
an overall consensus of 79 % (864/1092, Fig. 3). This varied 
depending on the antibiotic tested with the highest pairwise 
reporting consensus of 88 % (240/273) between participants 
for ciprofloxacin and the lowest pairwise reporting consensus 
of 72 % (197/273) for cefotaxime, which could be under-
standable given the different complexities of the resistance 
mechanisms involved. When we compared results from each 
participant with the phenotypic AST results, we found an 
overall sensitivity of 76 % and specificity of 50 %. The overall 
number of false positives was 64/316 (20 %) and the overall 
number of false negatives was 44/316 (14 %). Lab_5 had the 
highest number of false positives (14/40) and lowest number 
of false negatives (3/40), whereas Lab_1 had the lowest 
number of false positives (4/40) but the highest number of 
false negatives (7/40). Broken down by antibiotic, the highest 
consensus between phenotype and genotype was gentamicin 
(78%, 62/79) and the lowest amikacin (43 % 34/79). As 
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Fig. 2. Presence of AMR- associated genes in each sample by each team of participants. Genes are organized and coloured by the class 
of antibiotics their resistance is associated with. Genes are only shown here if reported by more than one participant and if they were 
present in more than one reference database used. MLS, Macrolide lincosamide and streptogramin.
expected, there was little agreement between predictions 
within the very low read depth sample (B-1) and most partici-
pants predicted a susceptible isolate due to missing data when 
in fact it was resistant by phenotypic AST. However, when 
analysing the same isolate at an appropriate higher read depth 
(B-2), there was near perfect concordance between partici-
pant reported genotypes and the resistance phenotype, with 
only two discrepant results reported by Lab_3 (ciprofloxacin) 
and Lab_7 (amikacin). Lab_3 also reported different results 
between the two identical samples (A-1 and A-2), where A-1 
was reported as resistant and A-2 was reported as sensitive. 
As there were no differences in the gene content reported in 
either sample by this participant (Fig. 2), this is likely to be 
due to a human reporting error. We also identified a single 
discrepancy between amikacin resistance predicted by Lab_7 
between samples C-1 and C-2, which both were sequenced 
from the same isolate. C-1 was reported as sensitive but C-2 
was reported as resistant, and the phenotypic AST result was 
sensitive; however, there was no difference in the reported 
gene content in both samples by Lab_7, so it is also another 
likely human reporting error. Excluding the extremely low 
depth sample, B-1, there were only 2/30 cases where no labo-
ratory correctly predicted the phenotypic AST result. Both 
of these results were an incorrect resistance prediction for 
amikacin in C-2 and E, but as noted earlier the prediction 
from Lab_7 for C-2 was likely human error.
DISCuSSIon
In this study, we have shown that participants using different 
choices of bioinformatics pipelines reported different AMR- 
associated gene variants when given identical mixed quality 
bacterial isolate WGS datasets. This led to differences in the 
reporting of predicted resistance phenotypes. We observed 
good concordance for genotypic- resistance predictions 
between participants, but poor concordance with phenotypic 
AST results. A similar trend has previously been seen in a 
study of Staphylococcus aureus genomes [39]. Concordance in 
phenotype prediction differed for different antibiotic classes. 
Good concordance was seen comparing WGS with AST 
results for gentamicin, but for amikacin concordance was 
poor. This may be due to the fact that amikacin is not affected 
by the action of most aminoglycoside- modifying enzymes 
[40]. Previous studies predicting antimicrobial susceptibility 
from WGS data have reported sensitivities of 96 and 99 % 
against phenotypic AST as a benchmark [21, 22], compared 
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Fig. 3. Concordance between phenotypic AST result and the genotypic prediction from WGS data. Results are presented separately for 
each participant, sample and antibiotic. Each tile is coloured based on whether both the resistant phenotype and genotype agreed (R/R); 
both phenotype and genotype predicted sensitive (S/S); major errors where the phenotype was sensitive, but the genotype was resistant 
(S/R); and very major errors where the phenotype was resistant, but the genotype was sensitive (R/S). Missing cells represent a result 
not reported.
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with an overall sensitivity of 76 % in this inter- laboratory 
study. It should be noted, however, that some of the data used 
in this study were purposefully very low quality, with some 
of the clinical isolates deliberately chosen to be difficult to 
characterize. Similar mixed quality data tested using current 
clinical AST phenotyping may also result in equivalent 
discrepancies. However, our aim here was to document the 
range of bioinformatics approaches being used and identify 
plausible contributors to discordant results reported between 
participants working on the same data, in order to provide 
useful recommendations and direct future work.
We identified three stages of analysis that contributed to 
discrepancies in predictions: the quality of the sequence data 
used, the bioinformatic methods (choice of database or soft-
ware used) and the interpretation of those results. Where single 
gene calling is required (e.g. presence of a carbapenemase), 
results are mainly affected by sequence quality. However, once 
multiple genes are involved, all three analytical issues become 
important. We found the largest contributors to discrepant 
results between the gene variants reported in each sample 
and the phenotypic resistance predictions were the sample 
sequence quality, read depth and the choice of reference 
resistance- gene database. Samples must be sequenced to a 
sufficient depth as well as sufficient breadth of coverage for the 
expected size of the genome, usually inferred by mapping to a 
suitable reference genome, of at least above 90 %. Based on our 
own experience and these results, we recommend 30× depth 
as a lower limit. This also tends to be a default setting for many 
read assembly tools, but generally most samples should have 
a higher depth of coverage than this for meaningful predic-
tion. Some participants did flag that they would not normally 
analyse the low depth of coverage samples (<30×, samples 
B-1, E and G) and if those samples are excluded from this 
analysis sensitivity in comparison to phenotypic AST rises 
from 76 to 98 %. This is highly encouraging as it suggests 
that as long as the sequence data produced is of sufficient 
depth and quality (e.g. current Illumina error rates) geno-
typic prediction of resistance phenotype can be comparable 
to AST. However, we also note that many sets of participants 
provided little information on their employment of quality 
control and filtering steps. Our results, therefore, suggest an 
increased emphasis on data quality control is highly relevant 
to improving sensitivity. Conversely, we have observed the 
choice of sequencer and DNA library preparation method 
has a small effect on closely related gene variants, but little 
discernible effect on the inference of resistance phenotype.
Some participants ran the same set of read data against 
different reference databases and merged the results, which 
led to different gene variants being reported at the same loci. 
In practice, different variants of the same gene may not always 
result in a different clinically relevant phenotype. However, 
we also found reference sequences in different databases 
for same gene variant can differ by 15 % nucleotide identity 
(blaIMP-1 in card and arg- annot). If precise identification 
of gene variants is required, we would strongly recommend 
avoiding this, as it effectively leads to ‘double- dipping’ using 
the same reads. Multiple reference databases could be used, 
but after screening for reads that have already been assigned 
a hit against one of the databases. This would avoid multiple 
different genes reported at the same genomic loci. However, 
it would be better to merge the different reference databases 
and remove the redundant sequences before comparisons are 
made against the test data. Sequence identity, and to lesser 
extent breadth of coverage cut- offs, should be kept high when 
comparing test data to a reference database. Based on this 
study, we would recommend using a sequence identity cut- off 
of at least 90%, in combination with an up to date curated 
reference resistance- gene database. Although lowering of 
these thresholds does identify more candidate genes within 
a sample, many were false negatives; thus, not improving 
concordance with phenotypic AST results in this study.
There is an overwhelming need for a standardized, central-
ized database that integrates the current knowledge base for 
linking genotype with resistance phenotype and is not linked 
to a single research group, as previously suggested [10]. There 
is also a growing need regarding computational reproduc-
ibility [41, 42]. This would deal with many of the issues we 
have raised, such as which sequences to include and what 
gene nomenclature to use. With strict version control, such a 
resource would allow greater integration of results and be an 
invaluable tool for larger epidemiological studies. Currently, 
databases are being built for organisms such as for Mycobac-
terium tuberculosis, though this is a less challenging organism 
for genotype–phenotype predictions due to it being highly 
clonal and lacking an accessory genome [43, 44]. A recent 
publication of a new protein- based database also obtained 
high concordance (98.4%) between genotype and phenotype 
for four food- borne pathogens [45]. However, for other clini-
cally relevant organisms there are limited resources.
Participants in this study included a mixture of individuals 
and teams involved in AMR prediction in a variety of settings. 
A potential criticism is that we did not restrict these settings 
to those routinely predicting AMR phenotype for clinical use, 
meaning that some participants were attempting analyses 
they did not usually perform. However, the fact that AMR 
phenotype prediction from WGS is not yet routine in most 
clinical laboratories was the very reason for undertaking this 
study. Clinical laboratories at the moment do not have the 
tools or knowledge to make good phenotypic resistance calls 
from genotypic data. This is evident from the fact that two 
participants in this study did not report any phenotypic resist-
ance predictions as they felt they could find no valid method 
for doing so. At this point in time, many research labora-
tories use these methods to track specific resistance genes 
or one specific resistance mechanism, rather than building 
tools for the broad detection of AMR in bacteria for clinical 
purposes. We found in this study that there was particularly 
low concordance between participants reporting sensitive 
isolates compared with phenotypic AST. The problem with the 
inference of phenotype from genotype is that the information 
either is not known at all or is expert knowledge restricted to 
single laboratories working on specific bacteria. In addition 
to this, although the identification of the presence of genes is 
performed in a systematic way, the prediction of resistance 
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is still performed in an ad hoc manner by scientists and, 
therefore, subject to user error given the same set of genes. 
Once again, M. tuberculosis is providing the first example of 
the need for a defined decision tree when working from the 
presence of genes or gene variants to the prediction of pheno-
typic drug resistance [46]. Interpretation and reporting of this 
genotypic data will need to be subjected to the same level of 
scrutiny as current tests if it is to form part of an accredited 
laboratory service within the healthcare service.
A limitation of this study is that we focused on the use of 
short- read sequence data, which produces sequences far 
shorter than the length of genes being identified. However, 
we feel this is more reflective of the WGS data that is more 
routinely generated in clinical laboratories at this point in 
time. If these short reads need to be assembled into longer 
contiguous sequences, we found it essential to use an actively 
developed short- read assembler such as SPAdes (http:// cab. 
spbu. ru/ software/ spades/). Web- hosted tools that provide a 
‘black box’ solution to assembly and identifying resistance 
from uploaded WGS data should be avoided if possible, 
because of the lack of interpretability. Tools are needed that 
are open source, designed for clinical purpose and can be 
subjected to thorough troubleshooting when erroneous results 
arise [47]. To this end, permanently employed bioinformati-
cians are required, who can provide expert interpretation of 
the results and update approaches as necessary. In this study, 
tools that either require assembled contigs (ABRicate) and 
those that take unassembled short reads (srst2 and ariba) 
were capable of producing very similar results with no notable 
effects alone on the predication of phenotypic resistance. This 
holds promise for rapid phenotypic predictions, as genome 
assembly is one of the largest bottlenecks in computational 
analysis time.
Other limitations of this study include our focus on acquired 
genes rather than point mutations or many of the other resist-
ance mechanisms found in bacteria (e.g. target site modifi-
cations and efflux pumps). We also only required reporting 
on categorical resistance predictions. Furthermore, because 
our focus was on WGS, and although we validated AST at 
two independent laboratories, we did not investigate poten-
tial variability and discordance in phenotypic prediction. 
More work needs to be done on the prediction of minimum 
inhibitory concentrations (MICs) from WGS data before it 
can be implemented in laboratories. This will be aided by 
more systematic reporting of accompanying MIC data when 
making WGS data available.
We have outlined recommendations for improving the 
current state of prediction of AMR from WGS data. Some of 
these recommendations, such as a standardized database and 
better dissemination of phenotype/genotype relationships, 
cannot be implemented immediately. However, current pipe-
lines can be improved right now by robust quality control of 
starting sequence reads to make sure that the genome breadth 
of coverage is high (>90 %) and that there is sufficient depth 
of coverage (>30×). We also recommended that running the 
same sequence read data set against multiple databases should 
be avoided due to the erroneous results, and that sequence 
identity between the predicted and reference AMR genes 
should be higher than 90 % to avoid non- specific hits. We 
found little difference between the results of participants 
depending on what reference database they chose to use, 
between which Illumina short- read sequencer was used and 
whether they used assembly or assembly- free methods.
In conclusion, we have identified some of the current 
contributors to discrepancies in predicting AMR- associated 
genes and phenotypes from bacterial isolate WGS data. We 
have provided recommendations for improving the current 
reporting of results. Despite its clear potential, even after 
accounting for poor sequence data, we found that the current 
public methods, in particular databases, are not adequate 
‘off- the- shelf ’ tools for the prediction of AMR from bacterial 
WGS data as a universal clinical test at this point in time.
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